Advertisement
Singapore markets closed
  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     
  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     
  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • Bitcoin USD

    64,069.48
    -441.78 (-0.68%)
     
  • CMC Crypto 200

    1,383.71
    -12.82 (-0.95%)
     
  • S&P 500

    5,106.54
    +58.12 (+1.15%)
     
  • Dow

    38,293.75
    +207.95 (+0.55%)
     
  • Nasdaq

    15,931.77
    +320.01 (+2.05%)
     
  • Gold

    2,352.50
    +10.00 (+0.43%)
     
  • Crude Oil

    83.71
    +0.14 (+0.17%)
     
  • 10-Yr Bond

    4.6730
    -0.0330 (-0.70%)
     
  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     
  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     
  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Gilead Sciences May Witness Significant Drop in Revenues in 2018

Gilead Sciences May Witness Significant Drop in Revenues in 2018

Gilead Sciences (GILD) expects to report net product sales in the range of $20.0 billion to $21.0 billion for full-year 2018. Compared to fiscal 2017, the company anticipates a negative impact attributable to declining hepatitis C (or HCV) drug sales in the range $5.1 billion to $5.6 billion in fiscal 2018. Additionally, Gilead Sciences has also projected a negative top-line impact in the range of $0.8 billion to $0. ...